Database Linkage Study to Evaluate the Risk of Medullary Thyroid Carcinoma

This is a database linkage study utilizing real-world data (RWD) to determine whether certain medicines used to treat type 2 diabetes (T2D) and support weight management (called GLP-1 RAs (Glucagon-like peptide-1 receptor agonists )) are linked to an increased risk of a rare cancer called medullary thyroid carcinoma (MTC). The purpose of this study is to compare how often medullary thyroid cancer occurs in people taking these medicines versus those taking other similar treatments. This study will use dispensed prescription claims and State Cancer Registry data to assess the risk of MTC.

Enrolling by Invitation

Interested in participating?

Request Info

Key information

Conditions

Medullary Thyroid Carcinoma Adenocarcinoma Carcinoma Carcinoma, Medullary Carcinoma, Neuroendocrine Neoplasms Neoplasms by Histologic Type Neoplasms, Ductal, Lobular, and Medullary Neoplasms, Germ Cell and Embryonal Neoplasms, Glandular and Epithelial Neoplasms, Nerve Tissue Neuroectodermal Tumors Neuroendocrine Tumors

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

IQVIA

Parsippany, New Jersey, 07054, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

18 years or older during the year of index (date of qualifying medication)
In addition to index medication, greater than or equal to (≥) 1 dispensed medication (any class) within 24 months prior to the index date1
≥1 dispensed medication (any class) after the index date and within 12 months of index date (12-month post-index period)
No evidence of cohort qualifying medication during 12-month before the index date
Reside in the US, including the District of Columbia (DC) during the study period
No missing values for year of birth

Exclusion criteria

Patients with a diagnosis of MTC in the linked SCR data before their index date will not be included in the study.

Treatment and study plan

No treatment given

Other

No treatment given

Primary outcomes

Time to first occurence of Medullary Thyroid Carcinoma (MTC)

Time frame: From day 1 up to 15 years

Measured in number of days.

Sponsors and collaborators

Lead sponsor

Novo Nordisk A/S

Industry

Registry information

Important dates

Study start: 2025
Primary completion: 2026
Study completion: 2026
First posted: Jul 20, 2026
Registry last updated: Jul 20, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Enrolling by Invitation